INSECTICID — Insecticides (India) Balance Sheet
0.000.00%
- IN₹15.11bn
- IN₹15.63bn
- IN₹21.40bn
Annual balance sheet for Insecticides (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | R2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 361 | 196 | 649 | 666 | 918 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,147 | 3,376 | 3,623 | 4,594 | 5,529 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10,027 | 12,322 | 12,524 | 14,251 | 14,478 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,326 | 3,722 | 4,111 | 4,263 | 4,770 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13,962 | 16,963 | 17,192 | 18,981 | 20,002 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5,078 | 7,595 | 6,638 | 7,775 | 7,404 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5,266 | 7,780 | 7,075 | 8,136 | 7,798 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 8,696 | 9,183 | 10,117 | 10,846 | 12,204 |
| Total Liabilities & Shareholders' Equity | 13,962 | 16,963 | 17,192 | 18,981 | 20,002 |
| Total Common Shares Outstanding |